This cluster groups 2 independently calculated changes: Cash & equivalents increased 116.0%; Operating cash flow increased 27.0%.
2 evidence-backed components· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTBluejay Diagnostics, Inc.'s latest supported as-filed period reports revenue of $249,040. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 116.0%; Operating cash flow increased 27.0%.
2 evidence-backed componentsShares outstanding changed +199.0% from the comparable as-filed period. The change ranks at the 100th percentile of 8 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BJDX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-098071SEC ↗4Aug 18, 2026Period Aug 17, 20260001123292-26-001127SEC ↗4Aug 18, 2026Period Aug 17, 20260001123292-26-001126SEC ↗4Aug 18, 2026Period Aug 17, 20260001123292-26-001125SEC ↗4Aug 18, 2026Period Aug 17, 20260001123292-26-001124SEC ↗4Aug 18, 2026Period Aug 17, 20260001123292-26-001123SEC ↗8-KAug 13, 2026Period Aug 13, 20260001213900-26-088701SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 18, 2026 | ZEIDMAN FRED SDirector | Grant Or AwardDirect | 100,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Cash & equivalents changed +116.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +106.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +103.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +80.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating cash flow changed +27.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed +61.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-088347